Condition

MRD (4)

AML (1)

Cytogenetic Abnormality (1)

MDS (1)

Molecular Abnormality (1)

Risk-directed Therapy (1)

SCT (1)

Overall Status

Unknown status (2)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 2 (2)

Sponsor

Guangdong Association of Clinical Trials (1)

Nanfang Hospital of Southern Medical University (1)

Nordic MDS Group (1)

Shanghai Tong Ren Hospital (1)

Intervention

adjuvant treatment for mrd positivity (1)

azacitidine (1)

justified risk stratification based on mrd after three course chemo therapy (1)

selinexor (1)

venetoclax (1)

Study Documents

Intervention Type

drug (1)

genetic (1)

other (1)

Funder Type

Other (4)

Study Type

Interventional (2)

Observational (2)

mrd

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

AML, MRD Trial in Shanghai (Azacitidine, Venetoclax, Selinexor)

Not yet recruiting

Azacitidine
+2 more

Shanghai, China
+3 more

Feb 12, 2023

MRD Trial in China (Adjuvant treatment for MRD positivity)

Recruiting

Adjuvant treatment for MRD positivity

Beijing, China
+15 more

Sep 12, 2022

Based on Molecular Cytogenetic Aberration and Treatment Response

Unknown status

Risk-directed Therapy
+3 more

Justified risk stratification based on MRD after three course chemo therapy

Guangzhou, Guangdong, China

Department of Hematology,Nanfang Hospital, Southern Medical Univ

Oct 31, 2019

MDS Patients After Allo-SCT

Unknown status

MDS
+2 more

Aarhus, Denmark
+7 more

Jan 29, 2018